Kymab and Seattle Children’s Research Institute publish impressive results using Kymab’s KY1005 in a model of Acute Graft versus Host Disease (aGVHD) in Science Translational Medicine

Kymab, an emerging biopharmaceutical company focused on the discovery and development of fully human monoclonal antibody drugs, announces that new data published in Science Translational Medicine indicate that Kymab’s most advanced clinical stage antibody, KY1005, could play an important role in blood-system transplants, such as the treatment of leukemia.